Evista
Trovati 8 articoli
- Postmenopausal women: Evista for reducing the risk of invasive breast cancer, FDA approved
- The FDA ( Food and Drug Administration ) approved Evista ( Raloxifene ) for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Evista is only the second drug approved to reduce the risk of brea... (Leggi Articolo)
- Postmenopausal women at increased risk for cardiovascular disease: Raloxifene associated with increased risk of stroke mortality
- Health Canada has informed Health Care Professionals of important new safety information regarding Evista ( Raloxifene ) resulting from the Raloxifene Use for The Heart ( RUTH ) trial. The RUTH trial, a large-scale placebo-controlled study, investigated whether a 60 mg daily dose of Raloxifene... (Leggi Articolo)
- Postmenopausal women at increased risk for cardiovascular disease: Raloxifene associated with increased risk of stroke mortality
- Health Canada has informed Health Care Professionals of important new safety information regarding Evista ( Raloxifene ) resulting from the Raloxifene Use for The Heart ( RUTH ) trial. The RUTH trial, a large-scale placebo-controlled study, investigated whether a 60 mg daily dose of Raloxifene... (Leggi Articolo)
- Prevention of invasive breast cancer: Evista as effective as Nolvadex
- Preliminary results of the STAR ( Study of Tamoxifen and Raloxifene ) trial showed that the drug Raloxifene ( Evista ), currently used to prevent and treat osteoporosis in postmenopausal women, works as well as Tamoxifen ( Nolvadex ) in reducing breast cancer risk for postmenopausal women at incr... (Leggi Articolo)
- Therapy of osteoporosis: an update
- Osteoporosis will affect one in three women over 50 and one in five men over 50. And as the elderly population grows worldwide, by 2050 the number of women and men that will suffer from osteoporosis-related hip fractures is set to increase by 240% and 310% respectively. At the International O... (Leggi Articolo)
- Higher fracture risk linked to poor persistence with osteoporosis drugs
- Independent studies of patients in Belgium, Canada, and Germany confirm that there is a major gap in treating patients with osteoporosis, despite the availability of a wide range of drugs, supplements and practices that help maintain and even build bone strength. Together, the studies demonstra... (Leggi Articolo)
- Breast cancer: breast-sparing surgery an option for women with BRCA mutations
- The women diagnosed with breast cancer who carry a certain genetic mutation can have breast-sparing surgery but should consider hormonal treatments to reduce their risk of cancer returning. A 10-year study, led by researchers at the University of Michigan, found that women with the genetic muta... (Leggi Articolo)
- Raloxifene and Tamoxifen are both effective in reducing the risk of invasive breast cancer but have different side effects
- Two studies found that Raloxifene ( Evista ) and Tamoxifen ( Novaldex ) are both effective in reducing the risk of invasive breast cancer, but each has potential disease and quality of life side effects that women and their physicians will need to consider. The papers are published in the JAMA... (Leggi Articolo)
